$NVAC
NorthView Acquisition Corp

2023 Q4 Form 10-Q Financial Statement

#000121390023088706 Filed on November 20, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $460.2K $290.1K
YoY Change 13.06% -28.27%
Operating Profit -$290.1K
YoY Change -28.27%
Interest Expense $145.4K $138.7K
YoY Change -88.98% -93.73%
% of Operating Profit
Other Income/Expense, Net $577.0K -$51.75K
YoY Change -102.34%
Pretax Income $262.3K -$341.8K
YoY Change -71.25% -118.92%
Income Tax $26.29K $25.50K
% Of Pretax Income 10.02%
Net Earnings $236.0K -$367.3K
YoY Change -51.1% -120.83%
Net Earnings / Revenue
Basic Earnings Per Share -$0.06
Diluted Earnings Per Share $0.04 $0.14
COMMON SHARES
Basic Shares Outstanding 6.168M shares 6.168M shares
Diluted Shares Outstanding 5.194M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.570M $17.34K
YoY Change 711.2% -95.35%
Cash & Equivalents $4.519K $17.34K
Short-Term Investments
Other Short-Term Assets $6.750K $135.6K
YoY Change -97.88% -59.23%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.576M $153.0K
YoY Change 208.06% -78.32%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $9.308M $10.65M
YoY Change -95.21% -94.48%
Total Long-Term Assets $9.308M $10.65M
YoY Change -95.21% -94.48%
TOTAL ASSETS
Total Short-Term Assets $1.576M $153.0K
Total Long-Term Assets $9.308M $10.65M
Total Assets $10.88M $10.80M
YoY Change -94.41% -94.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $449.1K $437.0K
YoY Change 0.14% 36.23%
Deferred Revenue
YoY Change
Short-Term Debt $200.0K $601.2K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.921M $2.999M
YoY Change 425.94% 649.26%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $156.6K $667.7K
YoY Change -81.74% -31.1%
Total Long-Term Liabilities $156.6K $667.7K
YoY Change -81.74% -31.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.921M $2.999M
Total Long-Term Liabilities $156.6K $667.7K
Total Liabilities $5.092M $3.667M
YoY Change 178.17% 167.77%
SHAREHOLDERS EQUITY
Retained Earnings -$3.460M -$3.484M
YoY Change 458.04% 830.58%
Common Stock $519.00 $519.00
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.459M -$3.483M
YoY Change
Total Liabilities & Shareholders Equity $10.88M $10.80M
YoY Change -94.41% -94.42%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $236.0K -$367.3K
YoY Change -51.1% -120.83%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$345.2K -$479.6K
YoY Change 92.48% 344.74%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$76.42K $146.3K
YoY Change 254633.33%
Cash From Investing Activities -$76.42K $146.3K
YoY Change 254633.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 408.8K 347.2K
YoY Change
NET CHANGE
Cash From Operating Activities -345.2K -479.6K
Cash From Investing Activities -76.42K 146.3K
Cash From Financing Activities 408.8K 347.2K
Net Change In Cash -12.83K 13.86K
YoY Change -92.85% -112.85%
FREE CASH FLOW
Cash From Operating Activities -$345.2K -$479.6K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5193750 shares
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
usd
CY2023Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5193750 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41177
dei Entity Registrant Name
EntityRegistrantName
NORTHVIEW ACQUISITION CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-3437271
dei Entity Address Address Line1
EntityAddressAddressLine1
207 West 25th St.,
dei Entity Address Address Line2
EntityAddressAddressLine2
9th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10001
dei City Area Code
CityAreaCode
(212)
dei Local Phone Number
LocalPhoneNumber
494-9022
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6167882 shares
CY2023Q3 us-gaap Cash
Cash
17342 usd
CY2022Q4 us-gaap Cash
Cash
193486 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
135625 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
318218 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
152967 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
511704 usd
CY2023Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
10651566 usd
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
194224782 usd
CY2023Q3 us-gaap Assets
Assets
10804533 usd
CY2022Q4 us-gaap Assets
Assets
194736486 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
437042 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
448480 usd
CY2023Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
1848455 usd
CY2023Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
57434 usd
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
462271 usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
601239 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2999170 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
935751 usd
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
36940 usd
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
667708 usd
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
857787 usd
CY2023Q3 us-gaap Liabilities
Liabilities
3666878 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1830478 usd
CY2023Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
974132 shares
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
18975000 shares
CY2023Q3 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.9
CY2022Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.2
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
10620981 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
193525484 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5193750 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5193750 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5193750 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5193750 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
519 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
519 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3483845 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-619995 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3483326 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-619476 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10804533 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
194736486 usd
CY2023Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
290098 usd
CY2022Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
404425 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1048525 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
863546 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-290098 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-404425 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1048525 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-863546 usd
CY2023Q3 us-gaap Interest Income Securities Other Us Government
InterestIncomeSecuritiesOtherUSGovernment
138725 usd
CY2022Q3 us-gaap Interest Income Securities Other Us Government
InterestIncomeSecuritiesOtherUSGovernment
1136826 usd
us-gaap Interest Income Securities Other Us Government
InterestIncomeSecuritiesOtherUSGovernment
2103111 usd
us-gaap Interest Income Securities Other Us Government
InterestIncomeSecuritiesOtherUSGovernment
1371326 usd
CY2023Q3 nvac Change In Fair Value Of Convertible Loan
ChangeInFairValueOfConvertibleLoan
53186 usd
nvac Change In Fair Value Of Convertible Loan
ChangeInFairValueOfConvertibleLoan
111776 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
243659 usd
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1074374 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-190079 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6246897 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-51748 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2211200 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2404966 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7618223 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-341846 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1806775 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1356441 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6754677 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25499 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
42962 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
430502 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
69484 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-367345 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
1763813 usd
us-gaap Net Income Loss
NetIncomeLoss
925939 usd
us-gaap Net Income Loss
NetIncomeLoss
6685193 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5193750 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5193750 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5193750 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5193750 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-619476 usd
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
1279617 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-1848455 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
440895 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-3306653 usd
CY2023Q2 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
419670 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
852389 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2873934 usd
CY2023Q3 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
242047 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-367345 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3483326 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-5909230 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
3709017 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-2200213 usd
CY2022Q2 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
132478 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
1212363 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1120328 usd
CY2022Q3 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
1017341 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
1763813 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-373856 usd
us-gaap Net Income Loss
NetIncomeLoss
925939 usd
us-gaap Net Income Loss
NetIncomeLoss
6685193 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
2103111 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1371326 usd
nvac Fair Value Adjustment Of Convertible Note
FairValueAdjustmentOfConvertibleNote
111776 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-190079 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6246897 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-182592 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-237418 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-11438 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
215900 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-404837 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
69484 usd
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
30000 usd
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
8387 usd
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-36940 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1719650 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-401841 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
340947 usd
us-gaap Proceeds From Decommissioning Fund
ProceedsFromDecommissioningFund
184845836 usd
us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
25000 usd
nvac Repayments Of Reimbursement Income Taxes From Trust Account
RepaymentsOfReimbursementIncomeTaxesFromTrustAccount
-1171438 usd
nvac Repayments Of Reimbursement Income Taxes From Trust Account
RepaymentsOfReimbursementIncomeTaxesFromTrustAccount
-8484 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
185676327 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
33484 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
713015 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
-184845836 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-184132821 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-176144 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-368357 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
193486 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
741228 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17342 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
372871 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
891437 usd
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
1848455 usd
us-gaap Stock Issued1
StockIssued1
1941334 usd
us-gaap Stock Issued1
StockIssued1
1149819 usd
CY2021Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
10
CY2021Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
189750000 usd
us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
1
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
7959726 usd
us-gaap Other Underwriting Expense
OtherUnderwritingExpense
3450000 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
3570576 usd
nvac Representative Warrants Cost
RepresentativeWarrantsCost
259527 usd
CY2023Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
679623 usd
CY2023Q3 us-gaap Fair Value Investments Entities That Calculate Net Asset Value Per Share Percent Arbitrage Investments
FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePercentArbitrageInvestments
0.80 pure
CY2021Q4 nvac Maturity Days
MaturityDays
P185D
CY2021Q4 us-gaap Shares Acquired Weighted Average Discount To Net Assets Percentage
SharesAcquiredWeightedAverageDiscountToNetAssetsPercentage
1 pure
us-gaap Other Expenses
OtherExpenses
100000 usd
nvac Net Tangible Assets
NetTangibleAssets
5000001 usd
CY2023Q3 us-gaap Cash
Cash
17342 usd
CY2023Q3 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
2846203 usd
us-gaap Partners Capital Account Contributions
PartnersCapitalAccountContributions
25000 usd
nvac Unsecured Promissory Note
UnsecuredPromissoryNote
204841 usd
CY2023Q2 nvac Working Capital
WorkingCapital
1200000 usd
CY2023Q2 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
1
CY2023Q2 nvac Outstanding Principal Amount
OutstandingPrincipalAmount
713015 usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
601239 usd
CY2023Q1 nvac Repurchase Percentage
RepurchasePercentage
1 pure
CY2023Q3 nvac Extension Payments
ExtensionPayments
146120 usd
nvac Extension Payments
ExtensionPayments
340947 usd
CY2023Q1 us-gaap Preferred Stock Redemption Amount
PreferredStockRedemptionAmount
184845836 usd
CY2022Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.01 pure
CY2023Q1 us-gaap Stock Redeemed Or Called During Period Shares
StockRedeemedOrCalledDuringPeriodShares
18000868 shares
CY2023Q1 us-gaap Payable Common Stock Redeemed
PayableCommonStockRedeemed
184845836 usd
CY2023Q3 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
1848455 usd
nvac Shares Redeemed Percentage
SharesRedeemedPercentage
0.01 pure
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account.</p>
CY2023Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
194224782 usd
CY2022 us-gaap Closed Block Dividend Obligation Change In Unrealized Investment Gains Losses
ClosedBlockDividendObligationChangeInUnrealizedInvestmentGainsLosses
43626 usd
CY2022 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
194268408 usd
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0746 pure
CY2022Q3 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0238 pure
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.3174 pure
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0103 pure
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
21 usd
CY2023Q3 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 usd
us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
19158 usd
CY2022Q3 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 usd
us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 usd
CY2023Q3 us-gaap Class Of Warrant Or Right Unissued
ClassOfWarrantOrRightUnissued
17404250 shares
CY2023Q3 us-gaap Limited Partners Offering Costs
LimitedPartnersOfferingCosts
7959726 usd
us-gaap Other Underwriting Expense
OtherUnderwritingExpense
3450000 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
3570576 usd
nvac Representatives Warrants Cost
RepresentativesWarrantsCost
259527 usd
CY2023Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
679623 usd
nvac Payment Of Stock Issuance Costs
PaymentOfStockIssuanceCosts
7701178 usd
nvac Shares Of Common Stock
SharesOfCommonStock
17404250 shares
CY2022 nvac Gross Proceeds
GrossProceeds
189750000 usd
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
4204248 usd
CY2022 us-gaap Proceeds From Issuance Of Common Limited Partners Units
ProceedsFromIssuanceOfCommonLimitedPartnersUnits
7701178 usd
CY2022 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
15680910 usd
CY2022 us-gaap Temporary Equity Other Changes
TemporaryEquityOtherChanges
193525484 usd
nvac Partial Redemption
PartialRedemption
-184845836 usd
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1941333 usd
us-gaap Temporary Equity Other Changes
TemporaryEquityOtherChanges
10620981 usd
CY2023Q3 us-gaap Net Asset Value Per Share
NetAssetValuePerShare
9.2
nvac Equity Proceed Ownership Percentage
EquityProceedOwnershipPercentage
0.60 pure
CY2023Q3 us-gaap Share Price
SharePrice
18
us-gaap Class Of Warrant Or Right Reason For Issuing To Nonemployees
ClassOfWarrantOrRightReasonForIssuingToNonemployees
●in whole and not in part; ●at a price of $0.01 per warrant; ●upon a minimum of 30 days’ prior written notice of redemption (the “30-day redemption period”); ●if, and only if, the last sale price of the common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.
CY2021Q2 us-gaap Sponsor Fees
SponsorFees
25000 usd
CY2021Q2 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
0.005
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
862500 shares
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On December 20, 2021, the Company effected a 1.1- for-1 stock dividend of its common stock, resulting in the Sponsor holding an aggregate of 4,743,750 shares of common stock. The Founder Shares include an aggregate of up to 618,750 shares subject to forfeiture if the over-allotment option is not exercised by the underwriters in full.
nvac Common Stock Exceeds Per Share
CommonStockExceedsPerShare
12
CY2023Q2 nvac Sponsor Amount
SponsorAmount
1200000 usd
CY2023Q2 nvac Price Per Warrant
PricePerWarrant
1
CY2023Q3 us-gaap Principal Amount Outstanding Of Loans Held In Portfolio
PrincipalAmountOutstandingOfLoansHeldInPortfolio
713015 usd
CY2023Q3 us-gaap Hybrid Instruments At Fair Value Net
HybridInstrumentsAtFairValueNet
601239 usd
CY2021Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
150000 usd
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
200000 usd
CY2023Q3 us-gaap Other Borrowings
OtherBorrowings
200000 usd
nvac Additional Advanced From Sponsor
AdditionalAdvancedFromSponsor
4841 usd
CY2022Q2 nvac Promissory Note
PromissoryNote
25000 usd
CY2023Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1500000 usd
nvac Warrants Price Per Share
WarrantsPricePerShare
1
nvac Rental Expenses
RentalExpenses
5000 usd
CY2023Q3 us-gaap Payment For Administrative Fees
PaymentForAdministrativeFees
0 usd
us-gaap Payment For Administrative Fees
PaymentForAdministrativeFees
30000 usd
CY2022Q3 nvac Accrued And Charged To Operating Expenses
AccruedAndChargedToOperatingExpenses
15000 usd
nvac Accrued And Charged To Operating Expenses
AccruedAndChargedToOperatingExpenses
48387 usd
nvac Business Combination Percentage
BusinessCombinationPercentage
0.0368 pure
nvac Gross Proceeds Amount
GrossProceedsAmount
6986250 usd
CY2023Q3 nvac Business Combination Percentage Rate
BusinessCombinationPercentageRate
0.0368 pure
CY2023Q3 nvac Cash Percentage
CashPercentage
0.275 pure
CY2023Q3 nvac Equity Percentage
EquityPercentage
0.725 pure
CY2021Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
3570576 usd
nvac Exercisable Per Share
ExercisablePerShare
11.5
CY2023Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023Q3 us-gaap Equity Fair Value Disclosure
EquityFairValueDisclosure
155000000 usd
CY2023Q3 us-gaap Preferred Stock Convertible Conversion Ratio
PreferredStockConvertibleConversionRatio
155000000 pure
CY2023Q3 us-gaap Additional Collateral Aggregate Fair Value
AdditionalCollateralAggregateFairValue
3875000 usd
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Sponsor Fees
SponsorFees
25000 usd
CY2021Q2 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
0.005
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
862500 shares
CY2021Q4 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
the Company effected a 1.1- for-1 stock dividend of its common stock, resulting in an aggregate of 4,743,750 Founder Shares issued and outstanding. On December 22, 2021, the Company has also issued 450,000 shares (Representative’s Shares) of common stock (which included 37,500 Representative Shares issued pursuant to the full exercise of the over-allotment option) at the consummation of the IPO to I-Bankers and Dawson James (and/or their designees).
CY2023Q3 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
5193750 shares
CY2022Q4 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
5193750 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5193750 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5193750 shares
CY2023Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
974132 shares
CY2022Q4 us-gaap Excess Stock Shares Outstanding
ExcessStockSharesOutstanding
18975000 shares
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
601239 usd
CY2023Q3 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1268947 usd
nvac Aggregate Value Of Public Warrants
AggregateValueOfPublicWarrants
351038 usd
CY2022 nvac Aggregate Value Of Public Warrants
AggregateValueOfPublicWarrants
450656 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.055 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0474 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y9M
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.033 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.077 pure
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
11.5
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
11.5
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
10.79 usd
CY2022 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
10.13 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
713015 usd
us-gaap Change In Unrealized Gain Loss On Hedged Item In Fair Value Hedge1
ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
-111776 usd
CY2023Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
601239 usd
CY2022Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
usd
CY2022Q3 nvac Change In Fair Value Of Convertible Loan
ChangeInFairValueOfConvertibleLoan
usd
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5193750 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5193750 shares
nvac Fair Value Adjustment Of Convertible Note
FairValueAdjustmentOfConvertibleNote
usd
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
usd
us-gaap Proceeds From Decommissioning Fund
ProceedsFromDecommissioningFund
usd
us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
usd
CY2022 nvac Gross Unrealized Losses
GrossUnrealizedLosses
usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001859807

Files In Submission

Name View Source Status
0001213900-23-088706-index-headers.html Edgar Link pending
0001213900-23-088706-index.html Edgar Link pending
0001213900-23-088706.txt Edgar Link pending
0001213900-23-088706-xbrl.zip Edgar Link pending
f10q0923ex31-1_northview.htm Edgar Link pending
f10q0923ex31-2_northview.htm Edgar Link pending
f10q0923ex32-1_northview.htm Edgar Link pending
f10q0923ex32-2_northview.htm Edgar Link pending
f10q0923_northview.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nvac-20230930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nvac-20230930_cal.xml Edgar Link unprocessable
nvac-20230930_lab.xml Edgar Link unprocessable
nvac-20230930_def.xml Edgar Link unprocessable
nvac-20230930_pre.xml Edgar Link unprocessable
f10q0923_northview_htm.xml Edgar Link completed